Eli Lilly and Company
OrganizationOn 11 shows in Markets & Investing this week · 0.7× usual · most on Thoughtful Money with Adam Taggart
Eli Lilly and Company is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by chemist and Civil War veteran Eli Lilly, the company develops, manufactures, and markets human pharmaceuticals globally.
Rank this week
Share of the conversation
0.5‰ of what listeners heard
Reach this week
Tone this week
- Neutral 5
- Positive 1
- Very positive 1
Share of the conversation
Mentions of Eli Lilly and Company per 1,000 mentions of anything, 7-day rolling, markets & investing.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Oct 22 | 1.72‰ | 4 |
| Oct 23 | 1.55‰ | 3 |
| Oct 24 | 1.60‰ | 1 |
| Oct 25 | 1.58‰ | 2 |
| Oct 26 | 1.93‰ | 8 |
| Oct 27 | 1.51‰ | 2 |
| Oct 28 | 1.77‰ | 9 |
| Oct 29 | 2.15‰ | 11 |
| Oct 30 | 2.58‰ | 10 |
| Oct 31 | 2.84‰ | 6 |
| Nov 1 | 2.82‰ | 2 |
| Nov 2 | 3.20‰ | 15 |
| Nov 3 | 3.30‰ | 4 |
| Nov 4 | 2.79‰ | 2 |
| Nov 5 | 2.35‰ | 3 |
| Nov 6 | 2.06‰ | 5 |
| Nov 7 | 1.80‰ | 1 |
| Nov 8 | 1.85‰ | 3 |
| Nov 9 | 1.16‰ | 3 |
| Nov 10 | 1.13‰ | 3 |
| Nov 11 | 1.20‰ | 3 |
| Nov 12 | 1.21‰ | 3 |
| Nov 13 | 0.93‰ | 1 |
| Nov 14 | 0.93‰ | 1 |
| Nov 15 | 0.79‰ | 1 |
| Nov 16 | 0.84‰ | 4 |
| Nov 17 | 0.77‰ | 2 |
| Nov 18 | 0.78‰ | 3 |
| Nov 20 | 0.67‰ | 2 |
| Nov 21 | 0.83‰ | 4 |
Why is it trending?· Last 30 days
Lilly’s obesity-drug lead drives comparisons, investment interest, and market discussion
Stock Movers repeatedly framed Novo Nordisk as having lost its obesity-market lead to Lilly, despite plans for more than 5 blockbuster drugs and more than $23 billion in new sales.[1][2][3]
Fast Money’s Tim Seymour said Lilly is “crushing it,” arguing Novo’s efforts to catch up are outweighed by Lilly’s acquisitions and product development.[4]
Fast Money also reported Lilly adding almost 3% as both drugmakers presented early, non-study findings that GLP-1 users had reduced biological age versus placebo.[5]
Other shows discussed Lilly as a large, cash-rich or highly valued company: WSJ’s David Wainer called it a $1 trillion company tied to GLP-1 drugs, while Motley Fool linked its Treasury holdings to potential long-term benefits.[6][7]
The shows differ in emphasis, with some focusing on Lilly’s competitive and stock performance, while others discussed its reporting preferences, branding, AI skepticism, or healthcare portfolio gains.[8][9][10]
Sources · 10 moments
- 1.Stock Movers · Novo Slides; Accenture Up; Arhaus UpgradeChloe Melley · Sep 21 · Listen at 2:22 ↗
“All right. Novo Nordisk. Disappointing investors here. They were hoping for more concrete turnaround plans from the drug maker. We know that it was first to market with these GLP -1 weight loss drugs, but it quickly lost its lead. to Eli Li”
- 2.Stock Movers · Novo Nordisk Slump, SocGen's 'Easy Wins', Berentzen Grupp DealCaroline Hepker · Sep 21 · Listen at 0:31 ↗
“Now, let's look at some of the stocks on the move today here in Europe. I'm Caroline Hepger with Lizzie Burton and we're joined by Bloomberg's breaking news editor, Louise Moon. So, let's get into the detail of Nova Nordisk unveiling their”
- 3.Stock Movers · Closing Bell: Paramount Rallies After Settling Lawsuits, Intel Soars, UPS SlipsBailey Lipschultz · Sep 21 · Listen at 5:05 ↗
“to this news overnight in Europe. So I want to look at ADRs of Novo Nordisk down about 8 % on the day today. This company, disappointing investors who are hoping for more concrete turnaround plans from the CEO after the drug maker lost its”
- 4.CNBC's "Fast Money" · Strong Dollar Keeps Climbing… And The Outlook For The Pharma Trade 10/5/26Tim Seymour · Oct 5 · Listen at 32:42 ↗
“You're impatient, I'm impatient. Lilly is just crushing it, right? So everything that Novo does to try to catch up, Lilly's got, you know, 10 times the weight in answers in the way that they go look at acquisitions and product development.”
Written by AI from the cited moments; every quote is checked against the transcript.
Who is saying what about Eli Lilly and Company
Verified quotes from the last 90 days: who made the most claims, and which way they leaned.
- Jordi Visser12 claims on 2 shows
“Why does Eli Lilly have a moat? Because you still have to go through the FDA.”
The Pomp Podcast · Nov 21 ↗ - Jim Cramer6 claims on 1 show
“Buy 25 straight out, and then you wait for a decline.”
Mad Money w/ Jim Cramer · Nov 4 ↗ - Alec Renehan5 claims on 1 show
“the market is roughly assuming sort of... nine to 11% profit growth for the next 10 years.”
Equity Mates Investing Podcast · Oct 18 ↗
23 more with Pro.
Discussed alongside
Names that come up in the same conversations as Eli Lilly and Company.
Embed this
Paste this on your site to show Eli Lilly and Company's current trend:
<iframe src="https://podlume.ai/embed/e/eli-lilly-and-company" width="360" height="220" style="border:0" loading="lazy" title="Eli Lilly and Company on PodLume Trends"></iframe>